EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications

Valeria Conti, Emanuela De Bellis, Graziamaria Corbi, Bruno Charlier, Viviana Izzo, Maria Claudia Russillo, Marianna Amboni, Marina Picillo, Cesa Lorella Maria Scaglione, Ilaria Cani, Calogero Edoardo Cicero, Alessandra Nicoletti und 4 weitere

Frontiers in Pharmacology · 07.04.2026 · 17

DOI: 10.3389/fphar.2026.1748932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.04.2026. Verfasst von Valeria Conti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana Del Farmaco, Ministero Della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Women with Parkinson’s Disease (PD) have higher plasma exposure to levodopa and are particularly prone to developing complications during chronic levodopa therapy. However, there are no longitudinal studies focusing on differences in levodopa pharmacokinetics and their correlation with clinical outcomes. This multicenter longitudinal study aimed to investigate sex-related differences in levodopa pharmacokinetics in levodopa-naïve PD patients, and to evaluate relationships with levodopa-related complications.

Methods

After a single dose of levodopa/DOPA-decarboxylase inhibitor, blood samples were collected at baseline and at two-year follow-up to measure pharmacokinetic parameters using UHPLC-MS. Clinical assessment included wearing-off Questionnaire and MDS-UPDRS scale. Multiple linear regression analyses were performed to identify predictors of pharmacokinetic parameters and levodopa-related complications. Results and Discussion The study population consisted of 28 PD patients (18 men, 10 women) followed for 2 years from the start of levodopa therapy. No differences were found between the sexes in clinical characteristics, daily levodopa-dosage, and use of other antiparkinsonian drugs. AUC and Cmax were higher in females than in males (p < 0.001), and sex influenced both of these parameters regardless of whether pharmacokinetic analysis was performed at baseline or at follow-up. Female sex was the best predictor of AUC and Cmax. DYS was found in 20% of females but in no males, and 90% of females showed wearing-off compared to 50% of males (p = 0.022). In females but not in males, the presence of wearing -off was correlated with AUC and Cmax at baseline and after 2 years of treatment. Compared to men, women with PD showed higher plasma levodopa levels since the initial administration and after chronic treatment. Measuring exposure to levodopa may be useful for optimising levodopa dosage since the start of treatment, thus preventing levodopa-related complications.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseasedyskinesialevodopamotor and non-motor fluctuationssexwearing off

Autor:innen und Institutionen

  • Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, Italy.
  • Clinical Pharmacology Unit, San Giovanni di Dio e Ruggi d'Aragona University Hospital, Salerno, Italy.
  • PhD School "Clinical and Translational Oncology (CTO)", Scuola Superiore Meridionale, University of Naples "Federico II", Naples, Italy.
  • Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
  • Postgraduate School of Clinical Pharmacology and Toxicology, University of Salerno, Baronissi (SA), Italy.
  • Neuroscience Section, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.

Förderung

  • Agenzia Italiana Del Farmaco, Ministero Della Salute

Zitieren

APA

Conti, V., De Bellis, E., Corbi, G., Charlier, B., Izzo, V., Russillo, M. C., Amboni, M., Picillo, M., Scaglione, C. L. M., Cani, I., Cicero, C. E., Nicoletti, A., Soricelli, A., Barone, P., Filippelli, A., & Pellecchia, M. T. (2026). Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1748932

Vancouver

Conti V, De Bellis E, Corbi G, Charlier B, Izzo V, Russillo MC, et al. Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1748932

BibTeX
@article{Conti2026,
  author = {Conti, Valeria and De Bellis, Emanuela and Corbi, Graziamaria and Charlier, Bruno and Izzo, Viviana and Russillo, Maria Claudia and Amboni, Marianna and Picillo, Marina and Scaglione, Cesa Lorella Maria and Cani, Ilaria and Cicero, Calogero Edoardo and Nicoletti, Alessandra and Soricelli, Andrea and Barone, Paolo and Filippelli, Amelia and Pellecchia, Maria Teresa},
  title = {Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1748932}
}
Kostenlos starten →